FDA rejects Actelion's Zavesca for rare NP-C disease
Actelion’s bid to get a new use approved for Gaucher disease drug Zavesca has suffered a setback after regulators in the USA asked more information on the drug as a treatment for a rarer condition
FDA panel backs InterMune's Esbriet for IPF
Shares in InterMune will soar today after advisors to the US Food and Drug Administration voted in favour of recommending Esbriet for approval as a treatment for lung scarring
Read more...
|